Back to all Current clinical trials
Back to all Current clinical trials
Keynote-B15
The trial is testing a potential new treatment for Muscle-invasive Bladder Cancer.
- Category
-
Trial status
Active, not recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
-
ERM Project ID
78742
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Patients with Muscle-invasive Bladder Cancer.
What is involved for you?
Patients in the trial may receive the investigational product enfortumab vedotin (EV) + pembrolizumab (pembro) or receive standard chemotherapy gemcitabine + cisplatin before having surgery to remove the bladder. Patients who are having the experimental treatment will continue to receive enfortumab vedotin (EV) + pembrolizumab (pembro) after surgery. During visits to the clinic all participants will have physical assessments, blood tests and scans to assess the status of the tumour.
